Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2009

01.07.2009 | Preclinical Study

Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant

verfasst von: Clare A. Thibodeaux, Xuefeng Liu, Gary L. Disbrow, Yiyu Zhang, Janice D. Rone, Bassem R. Haddad, Richard Schlegel

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

The Myc transcription factor is commonly dysregulated in many human cancers, including breast carcinomas. However, the precise role of Myc in the initiation and maintenance of malignancy is unclear. In this study we compared the ability of wild-type Myc (wt Myc) or Myc phosphorylation deficient mutants (T58A, S62A or T58A/S62A) to immortalize and transform human mammary epithelial cells (HMECs). All Myc constructs promoted cellular immortalization. As previously reported in other cells, the Myc T58A mutant tempered apoptotic responses and increased Myc protein stability in HMEC cells. More importantly, we now show that HMECs overexpressing the Myc T58A mutant acquire a unique cellular phenotype characterized by cell aggregation, detachment from the substrate and growth in liquid suspension. Coincident with these changes, the cells become anchorage-independent for growth in agarose. Previous studies have shown that wt Myc can collaborate with hTERT in inducing HMEC anchorage-independent growth. We have verified this observation and further shown that Myc T58A was a stronger facilitator of such co-transformation. Thus, our findings indicate that differences in Myc protein phosphorylation modulate its biological activity in human breast epithelial cells and specifically that the T58A mutation can facilitate both cellular immortalization and transformation. Finally, we used the isogenic cell lines generated in this study to identify a subset of genes whose expression is greatly altered during the transition from the immortal to the anchorage-independent states.
Literatur
4.
Zurück zum Zitat Hammond SL, Ham RG, Stampfer MR (1984) Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc Natl Acad Sci USA 81:5435–5439. doi:10.1073/pnas.81.17.5435 PubMedCrossRef Hammond SL, Ham RG, Stampfer MR (1984) Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc Natl Acad Sci USA 81:5435–5439. doi:10.​1073/​pnas.​81.​17.​5435 PubMedCrossRef
5.
Zurück zum Zitat Brenner AJ, Stampfer MR, Aldaz CM (1998) Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 17:199–205. doi:10.1038/sj.onc.1201919 PubMedCrossRef Brenner AJ, Stampfer MR, Aldaz CM (1998) Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 17:199–205. doi:10.​1038/​sj.​onc.​1201919 PubMedCrossRef
6.
Zurück zum Zitat Romanov SR, Kozakiewicz BK, Holst CR et al (2001) Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409:633–637. doi:10.1038/35054579 PubMedCrossRef Romanov SR, Kozakiewicz BK, Holst CR et al (2001) Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409:633–637. doi:10.​1038/​35054579 PubMedCrossRef
7.
Zurück zum Zitat Garbe JC, Holst CR, Bassett E et al (2007) Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. Cell Cycle 6:1927–1936PubMed Garbe JC, Holst CR, Bassett E et al (2007) Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. Cell Cycle 6:1927–1936PubMed
8.
Zurück zum Zitat Foster SA, Wong DJ, Barrett MT et al (1998) Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 18:1793–1801PubMed Foster SA, Wong DJ, Barrett MT et al (1998) Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 18:1793–1801PubMed
9.
Zurück zum Zitat Huschtscha LI, Noble JR, Neumann AA et al (1998) Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res 58:3508–3512PubMed Huschtscha LI, Noble JR, Neumann AA et al (1998) Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res 58:3508–3512PubMed
10.
13.
Zurück zum Zitat Kiyono T, Foster SA, Koop JI et al (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396:84–88. doi:10.1038/23962 PubMedCrossRef Kiyono T, Foster SA, Koop JI et al (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396:84–88. doi:10.​1038/​23962 PubMedCrossRef
14.
Zurück zum Zitat Nonet GH, Stampfer MR, Chin K et al (2001) The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 61:1250–1254PubMed Nonet GH, Stampfer MR, Chin K et al (2001) The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 61:1250–1254PubMed
15.
Zurück zum Zitat Dimri GP, Martinez JL, Jacobs JJ et al (2002) The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62:4736–4745PubMed Dimri GP, Martinez JL, Jacobs JJ et al (2002) The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62:4736–4745PubMed
19.
22.
Zurück zum Zitat Duss S, Andre S, Nicoulaz AL et al (2007) An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res 9:R38. doi:10.1186/bcr1734 PubMedCrossRef Duss S, Andre S, Nicoulaz AL et al (2007) An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res 9:R38. doi:10.​1186/​bcr1734 PubMedCrossRef
23.
Zurück zum Zitat Ayyanan A, Civenni G, Ciarloni L et al (2006) Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci USA 103:3799–3804. doi:10.1073/pnas.0600065103 PubMedCrossRef Ayyanan A, Civenni G, Ciarloni L et al (2006) Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci USA 103:3799–3804. doi:10.​1073/​pnas.​0600065103 PubMedCrossRef
27.
Zurück zum Zitat Kato GJ, Barrett J, Villa-Garcia M et al (1990) An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 10:5914–5920PubMed Kato GJ, Barrett J, Villa-Garcia M et al (1990) An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 10:5914–5920PubMed
29.
Zurück zum Zitat Henriksson M, Bakardjiev A, Klein G et al (1993) Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 8:3199–3209PubMed Henriksson M, Bakardjiev A, Klein G et al (1993) Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 8:3199–3209PubMed
30.
Zurück zum Zitat Pulverer BJ, Fisher C, Vousden K et al (1994) Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9:59–70PubMed Pulverer BJ, Fisher C, Vousden K et al (1994) Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9:59–70PubMed
31.
Zurück zum Zitat Bhatia K, Huppi K, Spangler G et al (1993) Point mutations in the c-Myc transactivation domain are common in Burkitt’s lymphoma and mouse plasmacytomas. Nat Genet 5:56–61. doi:10.1038/ng0993-56 PubMedCrossRef Bhatia K, Huppi K, Spangler G et al (1993) Point mutations in the c-Myc transactivation domain are common in Burkitt’s lymphoma and mouse plasmacytomas. Nat Genet 5:56–61. doi:10.​1038/​ng0993-56 PubMedCrossRef
32.
Zurück zum Zitat Albert T, Urlbauer B, Kohlhuber F et al (1994) Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt’s lymphoma cell lines. Oncogene 9:759–763PubMed Albert T, Urlbauer B, Kohlhuber F et al (1994) Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt’s lymphoma cell lines. Oncogene 9:759–763PubMed
34.
Zurück zum Zitat Lutterbach B, Hann SR (1994) Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14:5510–5522PubMed Lutterbach B, Hann SR (1994) Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14:5510–5522PubMed
41.
Zurück zum Zitat Yeh E, Cunningham M, Arnold H et al (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 6:308–318. doi:10.1038/ncb1110 PubMedCrossRef Yeh E, Cunningham M, Arnold H et al (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 6:308–318. doi:10.​1038/​ncb1110 PubMedCrossRef
46.
Zurück zum Zitat Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980–982, 984–986, 989–990PubMed Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980–982, 984–986, 989–990PubMed
50.
Zurück zum Zitat Suprynowicz FA, Sparkowski J, Baege A et al (2000) E5 oncoprotein mutants activate phosphoinositide 3-kinase independently of platelet-derived growth factor receptor activation. J Biol Chem 275:5111–5119. doi:10.1074/jbc.275.7.5111 PubMedCrossRef Suprynowicz FA, Sparkowski J, Baege A et al (2000) E5 oncoprotein mutants activate phosphoinositide 3-kinase independently of platelet-derived growth factor receptor activation. J Biol Chem 275:5111–5119. doi:10.​1074/​jbc.​275.​7.​5111 PubMedCrossRef
55.
Metadaten
Titel
Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant
verfasst von
Clare A. Thibodeaux
Xuefeng Liu
Gary L. Disbrow
Yiyu Zhang
Janice D. Rone
Bassem R. Haddad
Richard Schlegel
Publikationsdatum
01.07.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0127-x

Weitere Artikel der Ausgabe 2/2009

Breast Cancer Research and Treatment 2/2009 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.